<DOC>
	<DOC>NCT01118949</DOC>
	<brief_summary>The purpose is to assess the safety of Lacosamide in subjects with uncontrolled Primary Generalized Tonic-Clonic (PGTC) seizures with Idiopathic Generalized Epilepsy.</brief_summary>
	<brief_title>Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsy, Generalized</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject has a diagnosis of uncontrolled epilepsy with primary generalized tonicclonic (PGTC) seizures and idiopathic generalized epilepsy. Diagnosis should have been established by an electroencephalogram (EEG) with generalized spikewave discharges within 5 years of the screening visit Subject has â‰¥1 PGTC seizure within the 12 weeks prior to the screening visit Subject has a stable dose regimen of 1 to 3 marketed antiepileptic drug(s) (AEDs) with or without additional concurrent stable Vagus Nerve Stimulation (VNS). The VNS must have been in place for at least 6 months prior to study entry with constant settings for at least 28 days prior to the screening visit and during the Baseline Phase. Benzodiazepines will be counted as an AED Subject has a history of partialonset seizures or EEG findings consistent with partial onset seizures Subject has a history of status epilepticus within the 5year Period prior to Visit 1 Subject has a current or previous diagnosis of pseudoseizures, conversion disorders, or other nonepileptic ictal events Subject has any medical or psychiatric condition Subject has any history of alcohol or drug abuse Subject is currently taking felbamate Subject has ever taken vigabatrin and has no visual fields examination report available or if results of the examination are abnormal Subject is on a ketogenic diet Subject has a known sodium channelopathy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Primary Generalized Tonic-Clonic (PGTC) Seizures</keyword>
	<keyword>Absence Seizures</keyword>
	<keyword>Myoclonic Seizures</keyword>
	<keyword>Idiopathic Generalized Epilepsy (IGE)</keyword>
</DOC>